Study Explores Effect of Hybrid Closed-Loop Therapy on Diabetic Complications
By Elana Gotkine HealthDay Reporter
FRIDAY, Feb. 28, 2025 -- For young people with type 1 diabetes, hybrid closed-loop insulin delivery does not affect the rate of severe hypoglycemia and is associated with an increased risk for diabetic ketoacidosis, but it is also associated with a lower risk for hypoglycemic coma, according to a study published online in the February issue of The Lancet Diabetes & Endocrinology.
Beate Karges, M.D., from RWTH Aachen University in Germany, and colleagues conducted a population-based cohort study involving young people with type 1 diabetes participating in the Diabetes Prospective Follow-up initiative. Participants were aged 2 to 20 years, with a diabetes duration of more than one year. The analysis included 13,922 young people: 7,088 used closed-loop therapy and 6,834 used open-loop therapy.
The researchers found that the rate of ketoacidosis was higher for those using closed- versus open-loop therapy (1.74 versus 0.96 per 100 patient-years; incidence rate ratio, 1.81), while there was no significant between-group difference in the rate of severe hypoglycemia. The rate of hypoglycemic coma was significantly lower for individuals using closed- versus open-loop therapy (0.62 versus 0.91 per 100 patient-years; incidence rate ratio, 0.68). Compared with those in the open-loop therapy group, patients in the closed-loop therapy group had a lower hemoglobin A1c level, higher percentage of time in target glucose range of 3.9 to 10.0 mmol/L, and less glycemic variability. For those with an HbA1c of 8.5 percent or higher, the rate of ketoacidosis was particularly high in the closed-loop versus open-loop therapy group.
"The findings of this study could have clinical implications for the care of young people with type 1 diabetes," the authors write.
Several authors disclosed ties to the pharmaceutical and medical technology industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Rise in Prevalence of Obesity in Youth, Adults With T1DM Seen From 2008 to 2023
FRIDAY, April 4, 2025 -- From 2008-2011 to 2020-2023, there was an increase in the prevalence of obesity among youth and adults with type 1 diabetes, and glucagon-like peptide 1...
Low-Glucose Alerts Beneficial for Insulin-Treated Drivers With Diabetes
FRIDAY, March 21, 2025 -- For individuals with type 1 diabetes, low-glucose alerts improve the time below range for drivers and reduce the incidence of low glucose while driving...
GLP-1 RA Use Tied to Better Kidney Transplant Outcomes in Patients With Diabetes
TUESDAY, March 18, 2025 -- Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.